The shadow of generic challenges has long loomed above copyright’s iconic drug, Viagra, sparking questions about the outlook of related medicinal portfolios. While initial years saw significant returns, the exclusivity end has allowed the path for less expensive alternatives, potentially reducing profitability and creating a real danger escort fo